Results 31 to 40 of about 8,463 (257)

Aprepitant Inhibits JNK and p38/MAPK to Attenuate Inflammation and Suppresses Inflammatory Pain

Frontiers in Pharmacology, 2022
Substance P contributes to the pathogenesis of pain by acting on NK-1R, specialized sensory neurons that detect noxious stimuli. Aprepitant, an antagonist of NK-1R, is widely used to treat chemotherapy-induced nausea and vomiting.
Yang Yang, Wei Zhou, Xiuqi Xu, Xianxiu Ge, Fei Wang, Guang-Qin Zhang, Lin Miao, Xueting Deng   +7 more
doaj   +1 more source

The Effect of SP/NK1R on the Expression and Activity of Catalase and Superoxide Dismutase in Glioblastoma Cancer Cells

Biochemistry Research International, 2021
Introduction. Glioblastoma is the most malignant brain tumor with different therapeutic protocols, including surgery, radiotherapy, and chemotherapy. Substance P (SP), a peptide released by sensory nerves, increases cellular excitability by activating ...
Faranak Korfi, Hossein Javid, Reza Assaran Darban, Seyed Isaac Hashemy   +3 more
doaj   +1 more source

Proteomic and phosphoproteomic analysis reveals that neurokinin-1 receptor (NK1R) blockade with aprepitant in human keratinocytes activates a distinct subdomain of EGFR signaling: Implications for the anti-pruritic activity of NK1R antagonists [PDF]

, 2019
Background: Epidermal growth factor receptor (EGFR) inhibitors can cause serious cutaneous toxicities, including pruritus and papulopustular acneiform skin eruptions.
Boozalis, Emily, Burns, Robert F, Huang, Amy H, Khanna, Raveena, Krischak, Madison, Kwatra, Madan M, Kwatra, Shawn G, Nanni, Cory, Roberts, Callie M, Semenov, Yevgeniy R, Williams, Kyle A   +10 more
core   +2 more sources

Applicability of the National Comprehensive Cancer Network/Multinational Association of Supportive Care in Cancer Guidelines for Prevention and Management of Chemotherapy-Induced Nausea and Vomiting in Southeast Asia: A Consensus Statement. [PDF]

, 2017
A meeting of regional experts was convened in Manila, Philippines, to develop a resource-stratified chemotherapy-induced nausea and vomiting (CINV) management guideline. In patients treated with highly emetogenic chemotherapy in general clinical settings,
Abdullah, Matin M, Chan, Alexandre, Ishak, Wan Zamaniah B Wan, Kanesvaran, Ravindran, Ong-Cornel, Annielyn B, Villalon, Antonio H   +5 more
core   +2 more sources

Personalized Estimate of Chemotherapy-Induced Nausea and Vomiting: Development and External Validation of a Nomogram in Cancer Patients Receiving Highly/Moderately Emetogenic Chemotherapy. [PDF]

, 2016
Chemotherapy-induced nausea and vomiting (CINV) is presented in over 30% of cancer patients receiving highly/moderately emetogenic chemotherapy (HEC/MEC).
Chan, Alexandre, Chen, Likun, Hu, Zhihuang, Huang, Yan, Keefe, Dorothy, Liang, Wenhua, Ma, Yuxiang, Xue, Cong, Yang, Yunpeng, Zhang, Li, Zhao, Hongyun, Zhao, Yuanyuan   +11 more
core   +2 more sources

Acute emesis: moderately emetogenic chemotherapy [PDF]

, 2010
This paper is a review of the recommendations for the prophylaxis of acute emesis induced by moderately emetogenic chemotherapy as concluded at the third Perugia Consensus Conference, which took place in June 2009.
Bria, Emilio, Herrstedt, Jørn, Hesketh, Paul J, Rapoport, Bernardo, Rittenberg, Cynthia, Roila, Fausto, Warr, David   +6 more
core   +1 more source

A conceptually new treatment approach for relapsed glioblastoma: Coordinated undermining of survival paths with nine repurposed drugs (CUSP9) by the International Initiative for Accelerated Improvement of Glioblastoma Care [PDF]

, 2017
Kast, Richard E. et al.To improve prognosis in recurrent glioblastoma we developed a treatment protocol based on a combination of drugs not traditionally thought of as cytotoxic chemotherapy agents but that have a robust history of being well-tolerated ...
Halatsch, Marc-Eric, Kast, Richard E., Muñoz Sáez, Miguel   +2 more
core   +5 more sources

Association of ABCB1, 5-HT3B receptor and CYP2D6 genetic polymorphisms with ondansetron and metoclopramide antiemetic response in Indonesian cancer patients treated with highly emetogenic chemotherapy. [PDF]

, 2011
Our study shows that in Indonesian cancer patients treated with highly cytostatic emetogenic, carriership of the CTG haplotype of the ABCB1 gene is related to an increased risk of delayed chemotherapy-induced nausea and ...
Baak-Pablo, Renee F, Gelderblom, Hans, Guchelaar, Henk-Jan, Hakimi, Mohammad, Mustofa, Mustofa, Nortier, Johann W R, Perwitasari, Dyah A, van der Straaten, Robert J H M, Wessels, Judith A M   +8 more
core   +2 more sources

Aprepitant, an antiemetic agent, interferes with metal ion homeostasis of Candida auris and displays potent synergistic interactions with azole drugs

Virulence, 2020
With the rapid increase in the frequency of azole-resistant species, combination therapy appears to be a promising tool to augment the antifungal activity of azole drugs against resistant Candida species.
Hassan E. Eldesouky, Nadia A. Lanman, Tony R. Hazbun, Mohamed N. Seleem   +3 more
doaj   +1 more source

Consensus recommendations for the prevention of vomiting and nausea following high-emetic-risk chemotherapy [PDF]

, 2010
In this update of our 2005 document, we used an evidence-based approach whenever possible to formulate recommendations, emphasizing the results of controlled trials concerning the best use of antiemetic agents for the prevention of emesis and nausea ...
Ballatori, Enzo, Bria, Emilio, Einhorn, Lawrence H, Espersen, Birgitte, Grunberg, Steven, Herrstedt, Jørn, Hesketh, Paul, Kris, Mark G, Morrow, Gary, Rittenberg, Cynthia, Saito, Mitsue, Tonato, Maurizio   +11 more
core   +1 more source